Literature DB >> 9475354

Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

I Krause1, M Blank, Y Shoenfeld.   

Abstract

Intravenous immunoglobulins (IVIG) are therapeutic preparations of pooled normal polyspecific immunoglobulin G. We investigated the presence and the in vivo pathogenic potential of autoantibodies against phospholipids and DNA in several commercial IVIG preparations. The presence of autoantibodies and their antiidiotypic antibodies in the IVIG preparations was detected by ELISA. Naive mice were actively immunized with either IVIG preparations or pathogenic monoclonal antibodies (mAbs) against cardiolipin (CL) or DNA, in an attempt to induce autoimmune conditions. The mice were tested for the presence of mouse autoantibodies (auto-Abs) and for clinical parameters of autoimmune diseases. We found high levels of auto-Abs against a panel of phospholipids and DNA, as well as their antiidiotypic Abs, in all the IVIGs. Affinity studies pointed to a lower affinity of auto-Abs of IVIG origin to their respective antigens compared to pathogenic mAbs. Mice immunized with pathogenic anti-CL mAb had high levels of antiphospholipid auto-Abs, accompanied by thrombocytopenia, prolonged aPTT, and an increased fetal resorption rate. Mice immunized with pathogenic anti-DNA mAb had elevated anti-DNA and anti-CL auto-Abs, along with a high erythrocyte sedimentation rate, leukopenia, and significant proteinuria. Following immunization with IgGs from IVIG batches, mice developed high levels of auto-Abs against phospholipids and DNA, similar to mice immunized with pathogenic anti-DNA or anti-CL mAbs, but none of the mice expressed the clinical manifestations compatible with the presence of these autoantibodies. We conclude that commercial IVIG preparations contain high levels of antiphospholipid and anti-DNA auto-Abs, as well as their antiidiotypic Abs. Although these Abs induced the generation of mouse auto-Abs upon active immunization, following idiotypic manipulation they did not prove to be pathogenic in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9475354     DOI: 10.1023/a:1023239904856

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  58 in total

1.  Anti-idiotypes against autoantibodies to procoagulant factor VIII (VIII:C) in intravenous immunoglobulins.

Authors:  M D Kazatchkine; F Rossi; Y Sultan; U Nydegger
Journal:  Int Rev Immunol       Date:  1989       Impact factor: 5.311

Review 2.  Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

Authors:  U Andersson; L Björk; U Skansén-Saphir; J Andersson
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

3.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

4.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

5.  IgG autoantibody activity in normal mouse serum is controlled by IgM.

Authors:  M Adib; J Ragimbeau; S Avrameas; T Ternynck
Journal:  J Immunol       Date:  1990-12-01       Impact factor: 5.422

6.  Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin.

Authors:  J C Barton; G A Herrera; J H Galla; L F Bertoli; J Work; W J Koopman
Journal:  Am J Med       Date:  1987-03-23       Impact factor: 4.965

Review 7.  Role of IL-3 in the antiphospholipid syndrome.

Authors:  Y Shoenfeld; P Fishman
Journal:  Lupus       Date:  1994-08       Impact factor: 2.911

8.  Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies.

Authors:  M Blank; A Tincani; Y Shoenfeld
Journal:  J Rheumatol       Date:  1994-01       Impact factor: 4.666

9.  Induction of experimental anti-phospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype.

Authors:  M Blank; I Krause; M Ben-Bassat; Y Shoenfeld
Journal:  J Autoimmun       Date:  1992-08       Impact factor: 7.094

10.  Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis.

Authors:  F Rossi; D R Jayne; C M Lockwood; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

View more
  7 in total

Review 1.  Intravenous immunoglobulin for treatment of pemphigus.

Authors:  Lehavit Akerman; Daniel Mimouni; Michael David
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  Intravenous immunoglobulin therapy in antiphospholipid syndrome.

Authors:  Emiliana Konova
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; L Ashkenazi; Y Milner; M Frusic-Zlotkin; G J Anhalt; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

4.  Anti-phospholipid antibodies in serum from patients with Guillain-Barré syndrome.

Authors:  G Nakos; E Tziakou; L Maneta-Peyret; C Nassis; M E Lekka
Journal:  Intensive Care Med       Date:  2005-07-26       Impact factor: 17.440

5.  Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; A S Payne; G J Anhalt; C Avivi; I Barshack; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

6.  Lupus-specific kidney deposits of HSP90 are associated with altered IgG idiotypic interactions of anti-HSP90 autoantibodies.

Authors:  A Kenderov; V Minkova; D Mihailova; N Giltiay; S Kyurkchiev; I Kehayov; M Kazatchkine; S Kaveri; A Pashov
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

Review 7.  Intravenous immunoglobulin in lupus panniculitis.

Authors:  João Espírito Santo; M F Gomes; M J Gomes; L Peixoto; S C Pereira; A Acabado; J Freitas; G Vinhas de Sousa
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.